5 results on '"Annie Abiola"'
Search Results
2. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
- Author
-
Victorine A Mensah, Aly Gueye, Magatte Ndiaye, Nick J Edwards, Danny Wright, Nicholas A Anagnostou, Massamba Syll, Amy Ndaw, Annie Abiola, Carly Bliss, Jules-François Gomis, Ines Petersen, Caroline Ogwang, Tandakha Dieye, Nicola K Viebig, Alison M Lawrie, Rachel Roberts, Alfredo Nicosia, Babacar Faye, Oumar Gaye, Odile Leroy, Egeruan B Imoukhuede, Katie J Ewer, Philip Bejon, Adrian V S Hill, Badara Cisse, and MVVC group
- Subjects
Medicine ,Science - Abstract
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP (multiple epitope thrombospondin-related adhesion protein) have shown promising safety, immunogenicity and efficacy in sporozoite challenge studies. More recently, a study in Kenyan adults, similar to that reported here, showed substantial efficacy against P. falciparum infection. One hundred and twenty healthy male volunteers, living in a malaria endemic area of Senegal were randomised to receive either the Chimpanzee adenovirus (ChAd63) ME-TRAP as prime vaccination, followed eight weeks later by modified vaccinia Ankara (MVA) also encoding ME-TRAP as booster, or two doses of anti-rabies vaccine as a comparator. Prior to follow-up, antimalarials were administered to clear parasitaemia and then participants were monitored by PCR for malaria infection for eight weeks. The primary endpoint was time-to-infection with P. falciparum malaria, determined by two consecutive positive PCR results. Secondary endpoints included adverse event reporting, measures of cellular and humoral immunogenicity and a meta-analysis of combined vaccine efficacy with the parallel study in Kenyan adults.We show that this pre-erythrocytic malaria vaccine is safe and induces significant immunogenicity, with a peak T-cell response at seven days after boosting of 932 Spot Forming Cells (SFC)/106 Peripheral Blood Mononuclear Cells(PBMC) compared to 57 SFC/ 106 PBMCs in the control group. However, a vaccine efficacy was not observed: 12 of 57 ME-TRAP vaccinees became PCR positive during the intensive monitoring period as compared to 13 of the 58 controls (P = 0.80). This trial confirms that vaccine efficacy against malaria infection in adults may be rapidly assessed using this efficient and cost-effective clinical trial design. Further efficacy evaluation of this vectored candidate vaccine approach in other malaria transmission settings and age-de-escalation into the main target age groups for a malaria vaccine is in progress.
- Published
- 2016
- Full Text
- View/download PDF
3. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine–pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal
- Author
-
Faye, Babacar, Ndiaye, Magatte, Ndiaye, Jean Louis, Annie, Abiola, Tine, Roger Clement, Lo, Aminata Collé, Ndiaye, Mohamed, Sow, Doudou, De Sousa, Alexandra, and Gaye, Oumar
- Published
- 2011
- Full Text
- View/download PDF
4. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial
- Author
-
Roger Tine, Aminata C. Lo, Babacar Faye, Mamadou C Ba, J.L. Ndiaye, Magatte Ndiaye, Annie Abiola, Doudou Sow, Khadime Sylla, and Oumar Gaye
- Subjects
Male ,Chemistry, Pharmaceutical ,Genes, Protozoan ,Protozoan Proteins ,Artesunate ,Pharmacology ,Polymerase Chain Reaction ,Parasite Load ,law.invention ,Randomized controlled trial ,law ,Malaria, Falciparum ,Merozoite Surface Protein 1 ,Mefloquine ,Incidence (epidemiology) ,Artemisinins ,Senegal ,Drug Combinations ,Infectious Diseases ,Treatment Outcome ,Tolerability ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,lcsh:Arctic medicine. Tropical medicine ,Combination therapy ,Adolescent ,lcsh:RC955-962 ,Plasmodium falciparum ,Antigens, Protozoan ,Biology ,lcsh:Infectious and parasitic diseases ,Antimalarials ,Young Adult ,Internal medicine ,parasitic diseases ,medicine ,Humans ,lcsh:RC109-216 ,Adverse effect ,Base Sequence ,Research ,DNA, Protozoan ,medicine.disease ,biology.organism_classification ,Parasitology ,Malaria - Abstract
Background Prompt treatment of malaria attacks with arteminisin-based combination therapy (ACT) is an essential tool for malaria control. A new co-blister tablet of artesunate-mefloquine (AM) with 25 mg/kg mefloquine has been developed for the management of uncomplicated malaria attacks. This non-inferiority randomized trial, was conducted to evaluate the efficacy and safety of the new formulation of AM in comparison to artemether-lumefantrine (AL) for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in Senegal. Methods The study was carried out from September to December 2010 in two health centres in Senegal. The study end points included (i) PCR corrected adequate clinical and parasitological response (ACPR) at day 28, (ii) ACPR at days 42 and 63, (iii) parasites and fever clearance time, (iv) incidence of adverse events and patients biological profile at day 7 using the WHO 2003 protocol for anti-malarial drug evaluation. Results Overall, 310 patients were randomized to receive either AM (n = 157) or AL (n = 153). PCR corrected ACPR at day 28 was at 95.5% in the AM arm while that in the AL arm was at 96.7% (p = 0.83). Therapeutic efficacy was at 98.5% in the AM arm versus 98.2% in the AL group at day 42 (p = 1). At day 63, ACPR in the AM and AL arms was at 98.2% and 97.7%, respectively (p = 0.32). The two treatments were well tolerated with similar biological profile at day 7. However, dizziness was more frequent in the AM arm. Conclusion Artesunate-mefloquine (25 mg/Kg mefloquine) is efficacious and well-tolerated for the treatment of uncomplicated P. falciparum malaria in adult patients.
- Published
- 2012
5. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
- Author
-
Doudou Sow, Annie Abiola, Khadime Sylla, Babacar Faye, Kuaku Folly, Aminata Colé Lo, Oumar Gaye, Roger Tine, Leon Amath Ndiaye, Jean Louis Ndiaye, and Magatte Ndiaye
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Plasmodium falciparum ,Developing country ,Context (language use) ,Disease ,Amodiaquine ,Antimalarials ,Young Adult ,Artemisinin combination therapy ,parasitic diseases ,medicine ,Humans ,Artemisinin ,Malaria, Falciparum ,Intensive care medicine ,Child ,biology ,business.industry ,Public health ,medicine.disease ,biology.organism_classification ,Artemisinins ,Senegal ,Malaria ,Drug Combinations ,Infectious Diseases ,Child, Preschool ,Population Surveillance ,Immunology ,Quinolines ,Female ,business ,medicine.drug ,Research Article - Abstract
Background Malaria remains a major public health problem in developing countries. Then in these countries prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations for the Senegalese national malaria control program. Methods An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to assess the efficacy and safety of three combinations: dihydro-artemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO’s protocol for antimalarial drug evaluation was used to assess each outcome. Results Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ (n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety profile was noted in the 3 study groups. Conclusion In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs. However, it’s remains important to continue to monitor their efficacy. Trial registration PACTR 201305000552290.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.